- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Alex Moulson on How Companies Choose Which Biosimilars to Produce
We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other contract development and manufacturing organization (CDMOs) function and how companies choose which molecules to develop.
Being based in Europe can have unique challenges for a company like Polpharma Biologics, a contract development and manufacturing organization (CDMO) with facilities in Poland and the Netherlands that specializes in biologics. Despite facing hurdles such as navigating partnerships to commercialize in multiple markets, developing complex molecules for international partners, and figuring out how to handle coronavirus disease 2019 (COVID-19) with facilities in 2 countries, Polpharma Biologics has grown to become a powerhouse, having 7 biosimilars in its pipeline and partnerships with Sandoz and Bioeq.
We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other CDMOs function and how companies choose which molecules to develop.
To check out more of our coverage of Polpharma Biologics, click here.
To learn more about Polpharma's natalizumab clinical trial, click here.
To learn about Polpharma Biologics recent integration efforts, click here.
To learn more about Polpharma Biologics, click here.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
